AtorFen contains the lowest fully effective dose of fenofibrate and is a combination of two dyslipidemia treatments in one tablet.
The data from AtorFen’s study showed improvements in HDL-C, triglycerides, VLDL and fibrinogen compared with atorvastatin alone (Lipitor 40 mg) as well as better effect on non-HDL-C, LDL-C, triglycerides and total cholesterol compared with fenofibrate alone (Tricor 145 mg).
Under the terms of the alliance, Athena will obtain exclusive rights in certain emerging markets to manufacture, develop, register and commercialize Veloxis’ AtorFen along with third parties.
In addition, Athena will also establish and fund AtorFen manufacturing capabilities in India and through partnerships with regional and country level pharmaceutical companies to develop and, commercialize the product.
The product has been developed by Veloxis through Phase II in the US, which will transfer its technology for manufacturing of AtorFen to Athena, with all expenses funded by Athena, and Veloxis will retain 70% of all revenues generated.